Apr 21 2020KELOWNA BC / ACCESSWIRE / April 21 2020 / Lexaria Bioscience Corp (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria") a global innovator in drug delivery platforms has filed an important new patent application in the United States describing the use of its DehydraTECH™ technology for the delivery of antiviral drugs The technology would potentially be Aug 20 2020Lexaria's DehydraTECH technology is covered by issued and pending patents in over 40 countries around the world Lexaria's first patent was issued by USPTO in October 2016 (US 9 474 725 B1) providing 20 years of patent protection expiring June 2034 Multiple patents have been awarded since then and are expected in the future

Lexaria Bioscience announces RD agreement with British

Sep 01 2020Lexaria Bioscience announces RD agreement with British American Tobacco Kelowna British Columbia- August 31 2020 - Lexaria Bioscience Corp (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) a global innovator in drug delivery platforms announces that it has entered a research and development (RD) framework agreement with British American Tobacco

New Enhanced DehydraTECH ™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations KELOWNA BC / ACCESSWIRE / June 4 2019 / Lexaria Bioscience Corp (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) a drug delivery platform innovator has discovered improved performance characteristics of a new version of the DehydraTECH

Mar 16 2020Lexaria Bioscience Corp is a global innovator in drug delivery platforms Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream promoting healthier ingestion methods lower overall dosing and higher effectiveness for lipophilic active molecules

Sep 01 2020Lexaria Bioscience announces RD agreement with British American Tobacco Kelowna British Columbia- August 31 2020 - Lexaria Bioscience Corp (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) a global innovator in drug delivery platforms announces that it has entered a research and development (RD) framework agreement with British American Tobacco

Aug 15 2019Lexaria Bioscience Announces it has Received Four New Patents Lexaria Bioscience Corp (LXRP) (LXX CN) (the "Company" or "Lexaria") a global innovator in drug delivery platforms is pleased to announce that four of its pending patent applications via its wholly-owned subsidiary Poviva Corp have now been granted

Lexaria Bioscience Announces new DehydraTECH Innovation

Lexaria Bioscience Announces new DehydraTECH Innovation Files New Patents June 04 2019 | About: OTCPK:LXRP +0% XCNQ:LXX +0% New Enhanced DehydraTECH ™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations

Aug 31 2020Kelowna British Columbia – TheNewswire – August 31 2020 – Lexaria Bioscience Corp (OTC:LXRP) (CSE:LXX) (CNSX:LXX CN) (the "Company" or "Lexaria") a global innovator in drug delivery platforms announces that it has entered a research and development ("RD") framework agreement with British American Tobacco (Investments) Limited ("BAT") to investigate Lexaria's

Kelowna British Columbia-TheNewswire - August 31 2020 - Lexaria Bioscience Corp (OTC:LXRP) (CSE:LXX) (CNSX:LXX CN) (the Company or Lexaria) a global innovator in drug delivery platforms announces that it has entered a research and development (RD) framework agreement with British American Tobacco (Investments) Limited (BAT) to investigate Lexaria's technology for potential use

Kelowna British Columbia - TheNewswire - August 31 2020 - Lexaria Bioscience Corp (OTC:LXRP) (CSE:LXX) (CNSX:LXX CN) (the Company or Lexaria) a global innovator in drug delivery platforms announces that it has entered a research and development (RD) framework agreement with British American Tobacco (Investments) Limited (BAT) to investigate Lexaria's technology for potential use

Aug 20 2020LOS ANGELES CA / ACCESSWIRE / August 20 2020 / Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria") a global innovator in drug delivery platforms today announced that it will be presenting at the 12th annual LD 500 Conference on Tuesday September 1 2020 at 12:00 PM ET

Aug 27 2019Lexaria now holds granted patents in three patent families which now also includes claims for potential treatment of disease conditions Lexaria currently has approximately 60 patent applications pending across 10 different patent families About Lexaria Lexaria Bioscience Corp is a global innovator in drug delivery platforms

Lexaria Bioscience announces RD agreement with British American Tobacco Kelowna British Columbia- August 31 2020 - Lexaria Bioscience Corp (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) a global innovator in drug delivery platforms announces that it has entered a research and development (RD) framework agreement with British American Tobacco (Investments) Limited

Lexaria Bioscience Corp (LXRP) (LXX CN) (the "Company" or "Lexaria") a drug delivery platform innovator has discovered improved performance characteristics of a new version of the DehydraTECH ™ delivery platform initially suitable for use in solid oral dosage forms like capsules tablets and pills for the pharmaceutical medical and supplement markets

Lexaria Bioscience announces RD agreement with British

Aug 31 2020Kelowna British Columbia – TheNewswire – August 31 2020 – Lexaria Bioscience Corp (OTC:LXRP) (CSE:LXX) (CNSX:LXX CN) (the "Company" or "Lexaria") a global innovator in drug delivery platforms announces that it has entered a research and development ("RD") framework agreement with British American Tobacco (Investments) Limited ("BAT") to investigate Lexaria's

Aug 27 2019Lexaria now holds granted patents in three patent families which now also includes claims for potential treatment of disease conditions Lexaria currently has approximately 60 patent applications pending across 10 different patent families About Lexaria Lexaria Bioscience Corp is a global innovator in drug delivery platforms

Jun 04 2019Lexaria Bioscience Corp (LXRP) (LXX CN) (the "Company" or "Lexaria") a drug delivery platform innovator has discovered improved performance characteristics of a new version of the DehydraTECH delivery platform initially suitable for use in solid oral dosage forms like capsules tablets and pills for the pharmaceutical medical and supplement markets

Jun 04 2019Lexaria Bioscience Announces new DehydraTECH Innovation Files New Patents Tuesday June 4 2019 6:10 AM New Enhanced DehydraTECH ™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations

Lexaria Bioscience Corp a global innovator in drug delivery platforms is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15 2019 – "Stable ready-to-drink beverage compositions comprising lipophilic active agents" Lexaria's patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery

Apr 21 2020Lexaria will be filing for additional patent protection in many international markets related to the use of DehydraTECH for delivery of antiviral drugs About Lexaria Lexaria Bioscience Corp is a global innovator in drug delivery platforms

Aug 27 2019Lexaria Bioscience Corp (LXRP) (LXX CN) (the "Company" or "Lexaria") a global innovator in drug delivery platforms is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15 2019 – "Stable ready-to-drink beverage compositions comprising lipophilic active agents"

KELOWNA BC / ACCESSWIRE / June 4 2019 / Lexaria Bioscience Corp (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) a drug delivery platform innovator has discovered improved performance characteristics of a new version of the DehydraTECH™ delivery platform initially suitable for use in solid oral dosage forms like capsules tablets